Kalytera, in efforts to further this research, has partnered with the Hebrew University of Jerusalem and exclusively licensed synthetic cannabinoids KAL 436/9 and 671.
Kalytera researchers have studied the ability of KAL436/9 to improve bone fracture healing and strengthen bones in patients suffering Osteogenesis imperfecta (brittle bone disease).
Researchers are exploring KAL671 for preventing bone loss in mice with PWS. Thus far, it’s demonstrated the ability to restore bone growth and inhibit bone resorption. It is also non-toxic in preclinical animal models.
On the 13th of January 2016, Kalytera announced that they have entered a binding letter of intent to acquire securities of Talent Biotechs Ltd., a private Israel-based developer of CBD therapeutics. Under this agreement, they have made a non-refundable payment of $1,000,000. This acquisition will allow Kalytera to further tap into the wealth of Israeli research on medical marijuana.
Talent is performing pioneering studies on the treatment of graft versus host disease (GvHD) – a potential complication in bone marrow transplant patients – and they have gained four orphan drug designations in the US and Europe. In May of 2015, Chief Medical Officer of Talent, Moshe Yeshurun, M.D., published a study demonstrating CBD’s efficacy in dealing with complications resulting from bone marrow transplants.
